Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alzamend Neuro (ALZN)
NASDAQ:ALZN
Alzamend Neuro (ALZN) Stock Price & Analysis
167 Followers
ALZN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.74 - $11.91
Previous Close$0.74
Volume54.62K
Average Volume (3M)55.11K
Market Cap
$5.09M
Enterprise Value$4.81M
Total Cash (Recent Filing)$282.87K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.4
Beta0.97
Next Earnings
Mar 16, 2023EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding6,866,846
10 Day Avg. Volume43,820
30 Day Avg. Volume55,107
Standard Deviation0.22
R-Squared0.00002
Alpha-0.11
Financial Highlights & Ratios
Price to Book (P/B)-1.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$21.00Price Target Upside2654.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Alzamend Neuro News
PremiumCompany Announcements
Alzamend Neuro Executes Unregistered Equity and Warrants Sale
PremiumCompany Announcements
Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency
PremiumCompany Announcements
Alzamend Neuro Secures Funding Through Preferred Stock Sale
Ownership Overview
49.67% Insiders
14.55% Mutual Funds
1.39% Other Institutional Investors
34.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALZN FAQ
What was Alzamend Neuro’s price range in the past 12 months?
Alzamend Neuro lowest stock price was $0.74 and its highest was $11.91 in the past 12 months.
What is Alzamend Neuro’s market cap?
Currently, no data Available
When is Alzamend Neuro’s upcoming earnings report date?
Alzamend Neuro’s upcoming earnings report date is Mar 16, 2023 which is 399 days ago.
How were Alzamend Neuro’s earnings last quarter?
Alzamend Neuro released its earnings results on Mar 15, 2022. The company reported -$0.45 earnings per share for the quarter, the consensus estimate of -$0.45 by $0.
Is Alzamend Neuro overvalued?
According to Wall Street analysts Alzamend Neuro’s price is currently Undervalued.
Does Alzamend Neuro pay dividends?
Alzamend Neuro does not currently pay dividends.
What is Alzamend Neuro’s EPS estimate?
Alzamend Neuro’s EPS estimate is -$0.6.
How many shares outstanding does Alzamend Neuro have?
Alzamend Neuro has 6,866,846 shares outstanding.
What happened to Alzamend Neuro’s price movement after its last earnings report?
Alzamend Neuro reported an EPS of -$0.45 in its last earnings report, expectations of -$0.45. Following the earnings report the stock price went down -4.729%.
Which hedge fund is a major shareholder of Alzamend Neuro?
Currently, no hedge funds are holding shares in ALZN
---
Alzamend Neuro Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (2654.82% Upside)
$21.00 (2654.82% Upside)
Blogger Sentiment
Bullish
ALZN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.58%
12-Months-Change
Fundamentals
Return on Equity
-1489.09%
Trailing 12-Months
Asset Growth
-89.97%
Trailing 12-Months
Company Description
Alzamend Neuro
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient's immunological system to combat Alzheimer's.
---
ALZN Stock 12 Months Forecast
Average Price Target
$21.00
▲(2654.82% Upside)
Technical Analysis
Best Analysts Covering ALZN
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-71.09%
reiterated a buy rating 4 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -71.09% per trade.
---